GSK
Manufacturing · United Kingdom · 10K+ Employees
View Company Info for Free
Overview
Headquarters
79 New Oxford St, London, Greater London...Phone Number
+44 2080475000Website
www.gsk.comRevenue
$44 BillionStock Symbol
GSKIndustry
About GSK
GSK Org Chart
Is GSK your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if GSK had a recent Job posting/layoffs
Check out if GSK is spiking on competitors!
Check if GSK has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at GSK
Earning: See what the market has to say on GSK recently announced quarterly report
GSK, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once GSK has new funding data
Product Launch: Get notified when GSK launches new products
Recommended Actions
Find VP level buyers at GSK
Find more new buyers
Company Profile Activity
Activity Insights
GSK is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
GSK is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about GSK.
GSK Tech Stack
A closer look at the technologies used by GSK
Most Recent Scoops
GSK News & Media
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
— Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials in H2 2026 — — HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese (Putonghua) and at 7:30 a.m. EDT / 12:30 p.m. BST / 7:30 p.m. HKT in English —GSK hopes to take on Moderna as it moves mRNA flu vaccine to Phase III trial
The company progresses its mRNA-based candidate just under a month after Moderna won FDA approval for the first seasonal flu mRNA vaccine.GSK's Blenrep (belantamab mafodotin) combinations approved in Singapore for treatment of relapsed/refractory multiple myeloma
Two head-to-head phase III trials demonstrated superior efficacy, including overall survival versus a daratumumab-based triplet in DREAMM-7 Blenrep, a first-in-class anti-BCMA ADC, could transform treatment as early as first relapse where additional effective treatment options are needed[1],[2],[3] SINGAPORE, Aug. 19, 2026 /PRNewswire/ -- GSK Singapore today announced that the Singapore Health Sciences Authority (HSA) has approved Blenrep for the treatment of adults with relapsed or refractory mCould GSK plc (GSK)’s Pipeline Acceleration Unlock a New Growth Era?
On July 28, GSK plc (NYSE:GSK) reported its second-quarter financial results, delivering strong core operational performance and showcasing steady commercial momentum. The firm’s total Q2 turnover reached £8.4 billion, marking a 5% increase year-over-year at constant exchange rates (CER), while Core operating profit climbed 7% CER to £2.80 billion and Core EPS rose 9% CER […]
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GSK
GSK plc is a British multinational pharmaceutical and biotechnology company headquartered in London, United Kingdom. Established in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, GSK is the tenth-largest pharmaceutical company globally. The company discovers, develops, manufactures, and delivers medicines and vaccines with a rese... Read More